GM-CSF-based cancer vaccines (Q35005952)

5 August 2017

1 reference

title

GM-CSF-based cancer vaccines (English)

1 reference

5 August 2017

Glenn Dranoff

1

1 reference

5 August 2017

1 October 2002

1 reference

5 August 2017

Immunological Reviews

1 reference

5 August 2017

188

1 reference

5 August 2017

147-154

1 reference

Human tumor antigens recognized by T lymphocytes

5 August 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

New paths in human cancer serology

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

Angiostatin-mediated suppression of cancer metastases by primary neoplasms engineered to produce granulocyte/macrophage colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

Immunobiology of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

Differential tumor surveillance by natural killer (NK) and NKT cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

The central role of CD4(+) T cells in the antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

Antigens recognized by autologous antibody in patients with renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

Human neoplasms elicit multiple specific immune responses in the autologous host

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

Model predicting survival in stage I melanoma based on tumor progression

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: comparison of adenovirus- and retrovirus-mediated genetic transduction

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

Demonstration of a rational strategy for human prostate cancer gene therapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

Granulocyte/macrophage-colony-stimulating factor released by adenovirally transduced CT26 cells leads to the local expression of macrophage inflammatory protein 1alpha and accumulation of dendritic cells at vaccination sites in vivo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

Changes in the strength of co-stimulation through the B7/CD28 pathway alter functional T cell responses to altered peptide ligands

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

Granulocytes, macrophages, and dendritic cells arise from a common major histocompatibility complex class II-negative progenitor in mouse bone marrow

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

The basic science of gene therapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

Characterization of human colon cancer antigens recognized by autologous antibodies

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

Cancer antigens: immune recognition of self and altered self

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18813.X

7 January 2021

10.1034/J.1600-065X.2002.18813.X

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12445288